Bausch Health Companies Inc Stock Price, News & Analysis

Bausch + Lomb partners with Prevent Blindness for the seventh year during AMD Awareness Month, launching a campaign aimed at educating the public on Age-Related Macular Degeneration (AMD), which affects 16 million adults in the U.S. The initiative aims to raise awareness and funds, contributing $1 for each social media interaction, with a goal of $50,000. Bausch + Lomb's president emphasized the importance of eye examinations, as early diagnosis is crucial. The company also plans to release its Visionary Report to identify AMD education gaps.

Bausch Health Companies (BHC) has priced an offering of $1.0 billion in 6.125% senior secured notes due 2027. The proceeds will be utilized for refinancing efforts, encompassing existing loans and the redemption of senior notes due 2025. The refinancing will involve $2.5 billion in term loans and a $975 million revolving credit facility, contingent on the completion of the Bausch + Lomb IPO. The Notes are secured by existing assets and are offered under specific exemptions from registration laws.

Bausch Health Companies Inc. (NYSE/TSX: BHC) has launched a $1.0 billion offering of new senior secured notes due 2027. The company also plans to refinance its existing credit agreement, which includes approximately $2.5 billion in new term B loans and a $975 million revolving credit facility. Proceeds will fund the redemption of outstanding 6.125% and 9.000% senior notes due 2025 and related expenses. The redemption is conditional upon completing the refinancing and receiving at least $7.0 billion from related transactions. The offering is not registered under U.S. securities laws.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that Dr. Yehia Hashad will join Bausch + Lomb as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective January 31, 2022. Dr. Hashad brings over 25 years of experience in the pharmaceutical industry, with significant expertise in ophthalmic pharmaceuticals from Allergan/AbbVie and Novartis. His appointment aims to enhance the R&D capabilities at Bausch + Lomb, a leader in eye health products and services, as the company continues to innovate and build on its 170-year legacy.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to refinance its existing credit agreement, involving $2.5 billion in Term B loans and a $975 million revolving credit facility. The refinancing is contingent upon the initial public offering (IPO) of Bausch + Lomb, expected to enable Bausch Health to designate Bausch + Lomb as an unrestricted subsidiary. Additionally, the company plans to issue $1 billion in secured debt securities to facilitate the redemption of existing notes. The transactions are subject to market conditions and are expected to close in Q1 2022.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a significant step towards separating its eye health business by filing a Registration Statement on Form S-1 for a proposed IPO of its subsidiary, Bausch + Lomb. The IPO aims to sell common shares in both the U.S. and Canada, with specifics on share quantity and pricing yet to be determined. Major financial institutions like Morgan Stanley and Goldman Sachs are leading the offering, with market conditions influencing the timing and structure of the transaction. There are no assurances regarding the IPO's completion.

Bausch Health Companies (NYSE/TSX: BHC) will present a business and strategic update during a fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022. CEO Joseph C. Papa expressed enthusiasm regarding the progress in unlocking company value, highlighting that preparations for the IPOs of Bausch + Lomb and Solta are nearly complete, pending market and regulatory conditions. The presentation will be available on their Investor Relations page.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that CEO Joseph C. Papa will speak at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:00 a.m. ET. A live webcast of the event will be available on the company's Investor Relations page. Bausch Health is committed to improving lives through a range of healthcare products, focusing on eye health, gastroenterology, and dermatology.